Table 5.
RA |
IH |
|||||||
---|---|---|---|---|---|---|---|---|
Topical ocular |
Oral |
Topical ocular |
Oral |
|||||
Saline | Prop | Saline | Prop | Saline | Prop | Saline | Prop | |
Corneal thickness, μm | 142.0 ± 24.3 | 106.8 ± 8.0 | 109.8 ± 12.8 | 122.3 ± 22.1 | 146.8 ± 13.9 | 161.8 ± 31.9 | 122.3 ± 25.4 | 116.3 ± 12.1 |
n = 12 | n = 18** | n = 12## | n = 21## | n = 16 | n = 10§§ | n = 12## | n = 12## | |
No. corneal epithelial cells | 405.8 ± 9.7 | 162.6 ± 7.6 | 304.6 ± 18.5 | 180.9 ± 12.2 | 255.3 ± 24.3 | 171.2 ± 7.8 | 297.0 ± 16.9 | 187.9 ± 8.7 |
n = 12 | n = 18** | n = 12## | n = 21**## | n = 16§§ | n = 10** | n = 12 | n = 12** | |
Tortuosity index | 0.97 ± 0.02 | 0.96 ± 0.03 | 0.95 ± 0.03 | 0.94 ± 0.03 | 0.95 ± 0.02 | 0.94 ± 0.03 | 0.95 ± 0.03 | 0.95 ± 0.03 |
n = 11 | n = 19 | n = 16 | n = 21 | n = 19 | n = 18 | n = 5 | n = 18 | |
Artery diameter, μm | 25.5 ± 4 | 24.4 ± 3.8 | 27.9 ± 3.8 | 24 ± 3.6 | 29 ± 6.2 | 22.2 ± 4.5 | 30.5 ± 8.2 | 25.5 ± 6.3 |
n = 20 | n = 23 | n = 24 | n = 30 | n = 28 | n = 23 | n = 13 | n = 24 | |
Vein diameter, μm | 34.6 ± 8.1 | 36.3 ± 9.7 | 35.9 ± 8.3 | 38.2 ± 9.7 | 36.8 ± 8.3 | 34.8 ± 7 | 29.2 ± 4.6 | 34 ± 5.6 |
n = 21 | n = 21 | n = 24 | n = 27 | n = 20 | n = 20 | n = 9 | n = 18 | |
Neovascularization | 1063.7 ± 263.5 | 2126.1 ± 619.1** | 1354.0 ± 273.6 | 2013.6 ± 827.7* | 3112.3 ± 890.2§§ | 1661.3 ± 345.8** | 2176.6 ± 803.4##§§ | 1661.9 ± 237.3* |
Number cells in NFL/GCL | 210 ± 73 | 194 ± 38 | 348 ± 80 | 412 ± 169 | 148.7 ± 54.5 | 307.2 ± 26.1 | 298.2 ± 93 | 241.3 ± 61.6 |
n = 4 | n = 6 | n = 4 | n = 6 | n = 3 | n = 4* | n = 4 | n = 6 | |
Total retinal thickness, μm | 292.5 ± 14 | 274.3 ± 51.7 | 305.9 ± 33.2 | 240 ± 31 | 229.8 ± 14.3 | 468.9 ± 11.3 | 561 ± 50 | 314 ± 46.9 |
n = 4 | n = 10 | n = 6 | n = 8 | n = 4 | n = 4**§ | n = 4##§§ | n = 6** | |
NFL/GCL thickness, μm | 41.2 ± 7 | 34.5 ± 12.2 | 44.5 ± 7.5 | 32.4 ± 4.7 | 37.8 ± 7.6 | 68.1 ± 7.9 | 82.3 ± 21.2 | 50.4 ± 7.2 |
n = 4 | n = 10 | n = 6 | n = 8 | n = 4 | n = 4* | n = 4 | n = 6§ | |
IPL thickness, μm | 38.8 ± 6 | 41.6 ± 10.9 | 50 ± 8.7 | 40.1 ± 2.6 | 41.2 ± 5.4 | 93.6 ± 4.3 | 73.9 ± 5.6 | 58.7 ± 10 |
n = 4 | n = 10 | n = 6 | n = 8 | n = 4 | n = 4**§§ | n = 4 | n = 6# | |
INL thickness, μm | 67.4 ± 7.8 | 65.8 ± 15.9 | 60.4 ± 13.9 | 50.1 ± 3.4 | 47.4 ± 9 | 110.1 ± 2.2 | 128.8 ± 9.4 | 77.6 ± 12.7 |
n = 4 | n = 10 | n = 6 | n = 8 | n = 4 | n = 4** | n = 4##§§ | n = 6**§ | |
ONL thickness, μm | 101.5 ± 11.4 | 94.1 ± 12.8 | 95.3 ± 4.5 | 77.5 ± 14.8 | 75.4 ± 7.6 | 109.8 ± 12.6 | 163.5 ± 14.1 | 98 ± 9.8 |
n = 4 | n = 10 | n = 6 | n = 8 | n = 4 | n = 4* | n = 4##§§ | n = 6** |
Data are mean ± SD. One-way ANOVA with Bonferroni's post hoc test was used to compare data among the topical ocular or oral groups. Unpaired t-test was used to compare RA versus IH.
P < 0.05, **P < 0.01 saline versus propranolol; #P < 0.05, ##P < 0.01 topical ocular versus oral; §P < 0.05, §§P < 0.01 RA versus IH.
INL, inner nuclear layer; IPL, inner plexiform layer; NFL/GCL, nerve fiber layer/ganglion cell layer; ONL, outer nuclear layer; SD, standard deviation.